Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Chung, Eva ^a   Hsu, Chia Lin ^a   Kondo, Motonari ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BCL 2; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NOTCH RECEPTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; HEMATOPOIETIC STEM CELL; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MOUSE; MULTIPOTENT STEM CELL; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; T CELL LEUKEMIA; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL SEPARATION; CELL SURVIVAL; CYTOLOGY; FLOW CYTOMETRY; GENETICS; GRANULOCYTE; MACROPHAGE; METABOLISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL SEPARATION; CELL SURVIVAL; ENZYME ACTIVATION; FLOW CYTOMETRY; GRANULOCYTES; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELLS; MACROPHAGES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, NOTCH;

EID: 82555170606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028350     Document Type: Article

References (57)

1. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, et al. (2003) BIOLOGY OF HEMATOPOIETIC STEM CELLS AND PROGENITORS: Implications for Clinical Application. Annu Rev of Immunol 21: 759-806.
2. Rodriguez-Abreu D, Bordoni A, Zucca E, (2007) Epidemiology of hematological malignancies. Ann Oncol 18: i3-i8.
3. Vardiman JW, (2010) The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms. Chem Biol Interact 184: 16-20.
4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
5. Tefferi A, Skoda R, Vardiman JW, (2009) Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.(Clinical report). Nat Rev Clin Oncol 6: 627(611).
6. Vardiman JW, Harris NL, Brunning RD, (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
7. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
8. Emanuel PD, (2008) Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 22: 1335-1342.
9. Platanias LC, (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101: 4667-4679.
10. Bos J, (1989) RAS oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
11. Downward J, (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
12. Schubbert S, Shannon K, Bollag G, (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308.
13. Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, et al. (2004) Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103: 4243-4250.
14. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, et al. (2004) Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 101: 597-602.
15. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, et al. (2004) Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113: 528-538.
16. Zhang J, Wang J, Liu Y, Sidik H, Young KH, et al. (2009) Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 113: 1304-1314.
17. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, et al. (2009) Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells. PLoS Biol 7: e1000059.
18. Chalhoub N, Baker SJ, (2009) PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol: Mechanisms of Disease 4: 127-150.
19. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
20. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, et al. (2010) Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 115: 1406-1415.
21. Guo W, Lasky JL, Chang C-J, Mosessian S, Lewis X, et al. (2008) Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453: 529-533.
22. Yilmaz ÖH, Valdez R, Theisen BK, Guo W, Ferguson DO, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482.
23. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, et al. (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441: 518-522.
24. Raman M, Chen W, Cobb MH, (2007) Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112.
25. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, et al. (2000) Signal transduction mediated by the Ras//Raf//MEK//ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293.
26. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, et al. (1994) Transformation of Mammalian Cells by Constitutely Active MAP Kinase Kinase. Science 265: 966-970.
27. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, et al. (2000) A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene 19: 526-536.
28. Kondo M, Scherer DC, Miyamoto T, King AG, Akashi K, et al. (2000) Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature 407: 383-386.
29. Passegué E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL, (2005) Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 202: 1599-1611.
30. Braun BS, Archard JA, Van Ziffle JAG, Tuveson DA, Jacks TE, et al. (2006) Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood 108: 2041-2044.
31. Zhang J, Lodish HF, (2004) Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors. Blood 104: 1679-1687.
32. Tefferi A, Gilliland DG, (2007) Oncogenes in Myeloproliferative Disorders. Cell Cycle 6: 550-566.
33. Van Etten RA, Shannon KM, (2004) Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6: 547-552.
34. Reya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
35. Domen J, Gandy KL, Weissman IL, (1998) Systemic Overexpression of BCL-2 in the Hematopoietic System Protects Transgenic Mice From the Consequences of Lethal Irradiation. Blood 91: 2272-2282.
36. Strasser A, Harris AW, Jacks T, Cory S, (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339.
37. Weng AP, Ferrando AA, Lee W, Morris JP IV, Silverman LB, et al. (2004) Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia. Science 306: 269-271.
38. Chiang MY, Xu L, Shestova O, Histen G, L'Heureux S, et al. (2008) Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 118: 3181-3194.
39. Lai A, Kondo M, (2007) Indentification of a bone marrow precursor of the earliest thymocytes in adult mouse. Proc Natl Acad Sci USA 104: 6311-6316.
40. Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ, (2000) Notch1 Signaling Promotes the Maturation of CD4 and CD8 SP Thymocytes. Immunity 13: 73-84.
41. Blalock WL, Pearce M, Chang F, Lee JT, Pohnert SC, et al. (2001) Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells. Leukemia 15: 794-807.
42. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, et al. (2003) Signal transduction mediated by the Ras//Raf//MEK//ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293.
43. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.
44. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, et al. (2011) A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice. Science Trans Med 3: 76ra27.
45. Datta SR, Brunet A, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
46. Strasser A, Harris AW, Bath ML, Cory S, (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
47. Vaux DL, Cory S, Adams JM, (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442.
48. Aifantis I, Raetz E, Buonamici S, (2008) Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 8: 380-390.
49. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, et al. (2005) c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 106: 2452-2461.
50. Hsu C-L, King-Fleischman AG, Lai AY, Matsumoto Y, Weissman IL, et al. (2006) Antagonistic effect of CCAAT enhancer-binding protein-α and Pax5 in myeloid or lymphoid lineage choice in common lymphoid progenitors. Proc Natl Acad Sci USA 103: 672-677.
51. Hsu C-L, Kikuchi K, Kondo M, (2007) Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment. Blood 110: 1420-1428.
52. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, et al. (2004) Enhancement of Hematopoietic Stem Cell Repopulating Capacity and Self-Renewal in the Absence of the Transcription Factor C/EBPα. Immunity 21: 853-863.
53. Sears R, Leone G, DeGregori J, Nevins JR, (1999) Ras Enhances Myc Protein Stability. Mol Cell 3: 169-179.
54. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, et al. (2000) Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514.
55. Li LH, Nerlov C, Prendergast D, MacGregor D, Ziff EB, (1994) c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 13: 4070-4079.
56. Antonson P, Pray MG, Jacobsson A, Xanthopoulos KG, (1995) Myc Inhibits CCAAT/Enhancer-Binding Protein α-Gene Expression in HIB-1B Hibernoma Cells Through Interactions with the Core Promoter Region. Eur J Biochem 232: 397-403.
57. Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, et al. (2001) c-Myc Is a Critical Target for C/EBPα in Granulopoiesis. Mol Cell Biol 21: 3789-3806.